Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non-Small-Cell Lung Cancer

被引:5
作者
Miyazawa, Tomoyuki [1 ]
Otsubo, Kanji [1 ]
Sakai, Hiroki [1 ]
Kimura, Hiroyuki [1 ]
Chosokabe, Motohiro [2 ]
Morikawa, Kei [3 ]
Furuya, Naoki [3 ]
Marushima, Hideki [1 ]
Kojima, Koji [1 ]
Mineshita, Masamichi [3 ]
Koike, Junki [2 ]
Saji, Hisashi [1 ]
机构
[1] St Marianna Univ, Sch Med, Dept Chest Surg, Kawasaki, Kanagawa, Japan
[2] St Marianna Univ, Sch Med, Pathol, Kawasaki, Kanagawa, Japan
[3] St Marianna Univ, Sch Med, Dept Internal Med, Div Resp Med, Kawasaki, Kanagawa, Japan
关键词
non-small-cell lung cancer; PD-L1; FDG-PET; CT; POSITRON-EMISSION-TOMOGRAPHY; GLUCOSE-UPTAKE; TUMOR;
D O I
10.1177/10732748211038314
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background This study aimed to determine the relationship of programmed death-ligand 1 (PD-L1) expression and standardized uptake values in fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) with prognosis in non-small-cell lung cancer (NSCLC). Methods We retrospectively analyzed 328 NSCLC patients who underwent lobectomy/segmentectomy with lymph node dissection. PD-L1 expression was detected by immunohistochemically stained using the murine monoclonal antibody clone 22C3. The preoperative maximum standardized uptake value (SUVmax) of FDG-PET/CT at the primary lesion; pathological factors including histological type, microscopic lymphatic, venous, and pleural invasion; and lymph node metastases in resected specimens was determined. Significant prognostic clinicopathologic factors were analyzed by univariate and multivariate analyses. Results PD-L1 expression was higher in men, smokers, squamous cell carcinoma, advanced pathologic stages, positive venous invasion, positive pleural invasion, and high preoperative SUVmax (>= 3). Postoperative survival analysis showed that both PD-L1 expression and preoperative SUVmax were significantly negative prognostic factors in univariate analysis for overall survival (OS) (P = 0.0123 and P < 0.0001) and relapse-free survival (RFS) (P = 0.0012 and P < 0.0001). Kaplan-Meier survival curves showed that the OS and RFS were the best in patients with negative PD-L1 expression and SUVmax < 3, intermediate in patients with positive PD-L1 expression and SUVmax < 3 and those with negative PD-L1 expression and SUVmax >= 3, and poor in patients with positive PD-L1 expression and SUVmax >= 3. Conclusion Combining PD-L1 expression and preoperative FDG-PET/CT SUVmax in primary tumor might help in accurate prediction of postoperative prognosis in NSCLC patients.
引用
收藏
页数:9
相关论文
共 25 条
[1]   Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer [J].
Aggarwal, Charu ;
Thompson, Jeffrey C. ;
Chien, Austin L. ;
Quinn, Katie J. ;
Hwang, Wei-Ting ;
Black, Taylor A. ;
Yee, Stephanie S. ;
Christensen, Theresa E. ;
LaRiviere, Michael J. ;
Silva, Benjamin A. ;
Banks, Kimberly C. ;
Nagy, Rebecca J. ;
Helman, Elena ;
Berman, Abigail T. ;
Ciunci, Christine A. ;
Singh, Aditi P. ;
Wasser, Jeffrey S. ;
Bauml, Joshua M. ;
Langer, Corey J. ;
Cohen, Roger B. ;
Carpenter, Erica L. .
CLINICAL CANCER RESEARCH, 2020, 26 (10) :2354-2361
[2]   Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET [J].
Bahce, I. ;
Yaqub, M. ;
Smit, E. F. ;
Lammertsma, A. A. ;
van Dongen, G. A. M. S. ;
Hendrikse, N. H. .
LUNG CANCER, 2017, 107 :1-13
[3]   The Prognostic Significance of Maximum Standardized Uptake Value of Primary Tumor in Surgically Treated Non-Small-Cell Lung Cancer Patients: Analysis of 413 Cases [J].
Bille, Andrea ;
Okiror, Lawrence ;
Skanjeti, Andrea ;
Errico, Luca ;
Arena, Vincenzo ;
Penna, Daniele ;
Ardissone, Francesco ;
Pelosi, Ettore .
CLINICAL LUNG CANCER, 2013, 14 (02) :149-156
[4]   First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].
Carbone, D. P. ;
Reck, M. ;
Paz-Ares, L. ;
Creelan, B. ;
Horn, L. ;
Steins, M. ;
Felip, E. ;
van den Heuvel, M. M. ;
Ciuleanu, T. -E. ;
Badin, F. ;
Ready, N. ;
Hiltermann, T. J. N. ;
Nair, S. ;
Juergens, R. ;
Peters, S. ;
Minenza, E. ;
Wrangle, J. M. ;
Rodriguez-Abreu, D. ;
Borghaei, H. ;
Blumenschein, G. R. ;
Villaruz, L. C. ;
Havel, L. ;
Krejci, J. ;
Corral Jaime, J. ;
Chang, H. ;
Geese, W. J. ;
Bhagavatheeswaran, P. ;
Chen, A. C. ;
Socinski, M. A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426
[5]   Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].
Herbst, Roy S. ;
Baas, Paul ;
Kim, Dong-Wan ;
Felip, Enriqueta ;
Perez-Gracia, Jose L. ;
Han, Ji-Youn ;
Molina, Julian ;
Kim, Joo-Hang ;
Arvis, Catherine Dubos ;
Ahn, Myung-Ju ;
Majem, Margarita ;
Fidler, Mary J. ;
de Castro, Gilberto, Jr. ;
Garrido, Marcelo ;
Lubiniecki, Gregory M. ;
Shentu, Yue ;
Im, Ellie ;
Dolled-Filhart, Marisa ;
Garon, Edward B. .
LANCET, 2016, 387 (10027) :1540-1550
[6]   Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade [J].
Iwai, Y ;
Ishida, M ;
Tanaka, Y ;
Okazaki, T ;
Honjo, T ;
Minato, N .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (19) :12293-12297
[7]   Lung Cancer: A Classic Example of Tumor Escape and Progression While Providing Opportunities for Immunological Intervention [J].
Jadus, Martin R. ;
Natividad, Josephine ;
Mai, Anthony ;
Yi Ouyang ;
Lambrecht, Nils ;
Szabo, Sandor ;
Ge, Lisheng ;
Hoa, Neil ;
Dacosta-Iyer, Maria G. .
CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2012,
[8]   2-Deoxy-2-[fluorine-18] fluoro-D-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma [J].
Kaira, Kyoichi ;
Shimizu, Kimihiro ;
Kitahara, Shinsuke ;
Yajima, Toshiki ;
Atsumi, Jun ;
Kosaka, Takayuki ;
Ohtaki, Yoichi ;
Higuchi, Tetsuya ;
Oyama, Tetsunari ;
Asao, Takayuki ;
Mogi, Akira .
EUROPEAN JOURNAL OF CANCER, 2018, 101 :181-190
[9]   Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma [J].
Kasahara, Norimitsu ;
Kaira, Kyoichi ;
Bao, Pinjie ;
Higuchi, Tetsuya ;
Arisaka, Yukiko ;
Erkhem-Ochir, Bilguun ;
Sunaga, Noriaki ;
Ohtaki, Yoichi ;
Yajima, Toshiki ;
Kosaka, Takayuki ;
Oyama, Tetsunari ;
Yokobori, Takehiko ;
Asao, Takayuki ;
Nishiyama, Masahiko ;
Tsushima, Yoshito ;
Kuwano, Hiroyuki ;
Shimizu, Kimihiro ;
Mogi, Akira .
LUNG CANCER, 2018, 119 :71-77
[10]   A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project [J].
Kerr, Keith M. ;
Thunnissen, Erik ;
Dafni, Urania ;
Finn, Stephen P. ;
Bubendorf, Lukas ;
Soltemiann, Alex ;
Verbeken, Eric ;
Biernat, Wojciech ;
Warth, Arne ;
Marchetti, Antonio ;
Speel, Ernst-Jan M. ;
Pokharel, Sarawati ;
Quinn, Anne Marie ;
Monlchorst, Kim ;
Navarro, Atilio ;
Madsen, Line Bille ;
Radonic, Teodora ;
Wilson, Joan ;
De Luca, Graziano ;
Gray, Steven G. ;
Cheney, Richard ;
Savic, Spasenija ;
Martorell, Miguel ;
Muley, Thomas ;
Baas, Paul ;
Meldgaard, Peter ;
Blackhall, Fiona ;
Dingemans, Anne-Marie ;
Dziadziuszko, Rafal ;
Vansteenkiste, Johan ;
Weder, Walter ;
Polydoropoulou, Varvara ;
Geiger, Thomas ;
Kammler, Roswitha ;
Peters, Solange ;
Stahel, Rolf ;
Rosell, Rafael ;
Molina, Miguel Angel ;
Hiltbrunner, Anita ;
Marti, Nesa ;
Tsourti, Zoi ;
Zygoura, Panagiota ;
Nicolson, Marianne ;
Stevenson, David A. J. ;
Mathieson, William ;
Smit, Egbert ;
van Setten, Coralien ;
Soltermann, Alex ;
Rulle, Undine ;
Curioni, Alessandra .
LUNG CANCER, 2019, 131 :95-103